Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QBKPN
- Development stage
- Phase 2
- Lead developer
- Qu Biologics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
QBKPN is a lung-directed Site Specific Immunomodulator (SSI) developed by Qu Biologics. It is composed of inactivated *Klebsiella pneumoniae* and is designed to restore and enhance innate immune function specifically within the lung microenvironment. By mimicking an acute infection, QBKPN stimulates the recruitment and activation of innate effector cells, including M1-polarized macrophages and Natural Killer (NK) cells. NK cell activation is mediated through the NKG2D pathway, providing broad-spectrum anti-tumor and anti-viral activity. The therapy is administered subcutaneously to induce a systemic immune response that targets the lungs. QBKPN is currently being evaluated in clinical trials for the prevention and treatment of serious respiratory infections, including COVID-19, particularly in elderly populations with immunosenescence, and as an immunotherapy for non-small cell lung cancer (NSCLC).
- Brand names
- QBKPN SSI
- Other names
- inactivated Klebsiella pneumoniaeKlebsiella-derived investigational immunotherapeutic
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)PRR (Pattern recognition receptors)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on QBKPN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QBKPN.